Navigation Links
Tapestry Announces Strategy to Focus on TPI 287 Clinical Program
Date:10/26/2007

al approvals, patient recruitment, formulation and manufacturing difficulties, delays in finalizing and receiving approval of protocols, negotiations with regulatory agencies, or other factors; that human clinical trials may show that TPI 287 is unsafe and/or ineffective in treating cancer in humans. General implementation risks associated with development of TPI 287 include those that we are blocked or limited in the development of TPI 287 because of the intellectual property rights of third parties; that we are limited in our ability to obtain, maintain and enforce our own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; and that the Company's resources will be insufficient to continue development, whether as a result of the Company's inability to raise additional cash or otherwise. Additional risks, uncertainties and other factors are identified under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" in the Company's reports filed from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q for the periods ended March 28, 2007, and June 27, 2007. The Company cautions investors not to place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update publicly or revise any forward-looking statements, whether as a result of new or additional information, future events or otherwise.

Contact: Tapestry Pharmaceuticals, Inc.

Gordon Link

Senior Vice President, Chief Financial Officer

303-516-8500

glink@tapestrypharma.com

Investor: Laura Perry

Stern Investor Relations, Inc.

212-362-1200

laura@sternir.com

Media: Lloyd Benson/Dana Conti


'/>"/>

SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007 AACR Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  RegeneRx Biopharmaceuticals, ... clinical-stage drug development company focused on tissue protection, ... Finkelstein , President and Chief Executive Officer, will ... Renshaw Global Investment Conference, sponsored by H.C. ... held September 8-10, 2015 at the St. Regis ...
(Date:9/2/2015)... Sept. 2, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... its affiliate has entered into a definitive agreement under ... , Inc. (NASDAQ: SURG ) for $6.50 per ... payment, Synergetics stockholders will receive additional cash payments of ... are achieved following the closing.  The transaction is expected ...
(Date:9/2/2015)... , Sept. 2, 2015 Tumultuous market ... frenzy of health care M&A activity – have led ... access restrictions on pharmaceutical sales reps. This marks the ... access has crossed the halfway point, according to the ... and marketing firm ZS . ...
Breaking Medicine Technology:RegeneRx to Present at Rodman & Renshaw Global Investment Conference 2RegeneRx to Present at Rodman & Renshaw Global Investment Conference 3Valeant Pharmaceuticals To Acquire Synergetics USA 2Valeant Pharmaceuticals To Acquire Synergetics USA 3Valeant Pharmaceuticals To Acquire Synergetics USA 4Valeant Pharmaceuticals To Acquire Synergetics USA 5Crossing the threshold: More than half of physicians restrict access to sales reps 2Crossing the threshold: More than half of physicians restrict access to sales reps 3Crossing the threshold: More than half of physicians restrict access to sales reps 4Crossing the threshold: More than half of physicians restrict access to sales reps 5
... Limited (the "Company") and Celtic Therapeutics Holdings LP ("Celtic ... clinical trial of SG2000 in ovarian cancer.  The trial ... of the USA, and is now actively recruiting patients ... will evaluate the overall response rate of SG2000 in ...
... (NYSE: AZN ) today announced that ... extended the time to complete its review of ... (Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO) (Logo: ... Prescription Drug User Fee Act (PDUFA) date from ...
Cached Medicine Technology:Commencement of a Phase II Clinical Trial of SG2000 in Ovarian Cancer 2Commencement of a Phase II Clinical Trial of SG2000 in Ovarian Cancer 3U.S. Food and Drug Administration Extends Review Timeline for BRILINTA (Ticagrelor) New Drug Application 2
(Date:9/2/2015)... ... 02, 2015 , ... Ericson is a noted speaker and educator in the ... Director of Education for the Association for Clinical Documentation Improvement Specialists (ACDIS) where she ... Camps. She serves as a CDI subject matter expert for a variety of HCPro ...
(Date:9/2/2015)... ... 2015 , ... The 2015 China Overseas Investment and Entrepreneurship ... conference will be hosted at five star Beijing Kunlun Hotel and Diaoyutai State ... feature leading EB-5 industry professionals and Chinese private equity partners looking for international ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... the upper extremity surgical market, announced today that more than 600 successful patient ... in the hand. Plus, nearly 70 of these procedures have been on ...
(Date:9/2/2015)... , ... September 02, 2015 , ... On September 9, ... attend doTERRA’s annual convention, the largest single-company convention to date for the state of ... look forward to a tremendous event,” states David Stirling, doTERRA CEO. “One of the ...
(Date:9/2/2015)... ... , ... The payroll conference theme this year is "TAKING ... legislative updates, including unemployment, global payroll best practices, and the latest trends in ... the American Payroll Association, Barnett Associates, and the IRS, will keep payroll professionals ...
Breaking Medicine News(10 mins):Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2
... A factor, once known as oscillin, carried by ... oscillations in free calcium necessary to bring about a ... is a strong candidate for oscillin. Eventually PLCZ1 undergoes ... to promote calcium oscillations ceases. One would reasonably think ...
... Representatives not to Concur on Senate Budget,which Includes Elimination ... May 23 Many older,Illinoisans were left out of ... includes severe cuts to several programs and,services that allow ... own choice and avoid costly and premature,institutional care. AARP ...
... 23 Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ... Bisaro, Watson,s president and chief,executive officer, will provide ... the UBS Global Specialty and Generic Pharmaceuticals Conference,on ... BST (9:30 a.m. EDT)., This presentation will ...
... the Army,s 2nd Battalion, 113th Infantry Regiment yesterday ... for their upcoming,deployment in Iraq. Instead of shooting ... procedure that allows them to have 20/20 vision ... Drs. Joseph and Jeffery Dello Russo marked ...
... In response to the,devastating 7.9 magnitude earthquake that ... public and corporations have generously supported,American Red Cross ... grateful for the outpouring of compassion,we,ve received from ... Meltzer, senior vice president, International Services for the,American ...
... condition can strike anyone , , FRIDAY, May 23 (HealthDay News) ... a four-time NBA All-Star, and head coach of the Philadelphia ... gout. , "I had no idea what gout was," Cheeks ... 46 -- with the often-debilitating arthritic condition. "Never heard of ...
Cached Medicine News:Health News:June 2008 highlights 2Health News:Soldiers Receive Free Memorial Day Lasik Surgery Before Going to Iraq 2Health News:America Generously Responds to China Earthquake 2Health News:Basketball Star Details His Struggle With Gout 2Health News:Basketball Star Details His Struggle With Gout 3
... Thyroid Autoimmunity Test is an enzyme immunoassay ... autoantibodies against human thyroglobulin and human thyroid ... blood and is used as an aid ... thyroid gland disorders are characterized by detection ...
The ImmunoWELL TPO IgG Quantitative Test is a quantitative enzyme immunoassay (EIA) for screening and detection of autoantibodies against human thyroid peroxidase (microsome) in serum and is used as ...
... The ImmunoDOT Autoimmunity Screening Panel 1 ... for screening and detection of autoantibodies ... DNA, SS-A/SS-B, RNP/Sm) in serum, and ... the diagnosis of systemic lupus erythematosus ...
... Autoimmunity Screening Panel 4 is an ... and detection of autoantibodies against various ... RNP/Sm, and Sm) in serum, and ... the diagnosis of systemic lupus erythematosus ...
Medicine Products: